Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Daman AW, Josefowicz SZ. Epigenetic and transcriptional control of interferon-β. J Exp Med. 2021;218(9).

Tong J, Luo J, Saldinger PF, Rodgers WH. A Rare Case of Histiocytic Sarcoma Secondary to Gastrointestinal Stromal Tumor in the Stomach: Transdifferentiation or Synchronicity? Case Rep Hematol. 2021;2021:8856649.

Plotz B, Castillo R, Melamed J, Magro C, Rosenthal P, H Belmont M. Focal small bowel thrombotic microvascular injury in COVID-19 mediated by the lectin complement pathway masquerading as lupus enteritis. Rheumatology (Oxford). 2021;60(2):e61-e63.

Ghantous Y, Omar M, Broner EC, Agrawal N, Pearson AT, Rosenberg AJ, et al. A robust and interpretable gene signature for predicting the lymph node status of primary T1/T2 oral cavity squamous cell carcinoma. Int J Cancer. 2021.

Soshnev AA, C Allis D, Cesarman E, Melnick AM. Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer. Cancer Res. 2021.

Che M, Chaturvedi A, Munro SA, Pitzen SP, Ling A, Zhang W, et al. Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. Nat Commun. 2021;12(1):6377.

Chen C-, Chen B-, Wang Y, Curman P, Beilinson HA, Brecht RM, et al. Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activity is required for V(D)J recombination. J Exp Med. 2021;218(8).

Conteduca V, Ku S-, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, et al. Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ Precis Oncol. 2021;5(1):84.

Nam G, Singh K, Lopresti ML, Ouseph MM, Wang LJ, Wang Y. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study. Technol Cancer Res Treat. 2021;20:15330338211035037.

Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, et al. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. Am J Surg Pathol. 2021;45(3):384-393.